About Partitioning defective 6 homolog beta
Partitioning defective 6 homolog beta (PARD6B) is a protein
from Homo sapiens identified by UniProt accession
Q9BYG5, 372 residues long.
MolForge cross-references it against 0 known binders and
70 disease associations.
Target properties
| Protein name | Partitioning defective 6 homolog beta |
| UniProt accession | Q9BYG5 |
| Gene | PARD6B |
| Organism | Homo sapiens |
| Length | 372 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (70)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.35
- colorectal cancer · score 0.33
- serum gamma-glutamyl transferase measurement · score 0.32
- breast adenocarcinoma · score 0.25
- endometrial cancer · score 0.23
- glioblastoma multiforme · score 0.16
- gastric carcinoma · score 0.15
- head and neck squamous cell carcinoma · score 0.15
- monocyte percentage of leukocytes · score 0.14
- gastric adenocarcinoma · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9BYG5-F1 | alphafold | PREDICTED | 70.46 | — |
Amino-acid sequence (372 residues)
MNRSHRHGAG SGCLGTMEVK SKFGAEFRRF SLERSKPGKF EEFYGLLQHV HKIPNVDVLV GYADIHGDLL PINNDDNYHK AVSTANPLLR IFIQKKEEAD YSAFGTDTLI KKKNVLTNVL RPDNHRKKPH IVISMPQDFR PVSSIIDVDI LPETHRRVRL YKYGTEKPLG FYIRDGSSVR VTPHGLEKVP GIFISRLVPG GLAQSTGLLA VNDEVLEVNG IEVSGKSLDQ VTDMMIANSR NLIITVRPAN QRNNVVRNSR TSGSSGQSTD NSLLGYPQQI EPSFEPEDED SEEDDIIIED NGVPQQIPKA VPNTESLESL TQIELSFESG QNGFIPSNEV SLAAIASSSN TEFETHAPDQ KLLEEDGTII TL
Explore Partitioning defective 6 homolog beta with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets